IL6R and rheumatoid arthritis: Tocilizumab (TCZ, which globally blocks IL-6 activities through IL-6R-α and sIL-6R) [79,80], when used in treating rheumatoid arthritis, is associated with adverse cardiovascular events [81] and an increase in serum cholesterol [82], which increases cardiovascular risk [83,84].